Serum, plasma, tissue homogenates and other biological fluids.
Species Reactivity
Mouse
Detection Method
sELSIA
Intended Use
For quantitative detection of ANA in serum, plasma, tissue homogenates and other biological fluids.
Contents of Kit
No.
Components
Size
Storage Conditions
1
ELISA Microplate(Dismountable)
8×12
2-8°C/-20°C
2
Lyophilized Standard
2vial
2-8°C/-20°C
3
Sample Dilution Buffer
20ml
2-8°C
4
Biotin-labeled Antigen (Concentrated)
120μl
2-8°C(Avoid Direct Light)
5
Antigen Dilution Buffer
10ml
2-8°C
6
HRP-Streptavidin Conjugate(SABC)
120μl
2-8°C(Avoid Direct Light)
7
SABC Dilution Buffer
10ml
2-8°C
8
TMB Substrate
10ml
2-8°C(Avoid Direct Light)
9
Stop Solution
10ml
2-8°C
10
Wash Buffer(25×)
30ml
2-8°C
11
Plate Sealer
5pieces
12
Product Description
1copy
Storage
2-8°C
Performance Characteristics
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% within the expiration date under appropriate storage condition. To minimize extra influence on performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is strongly suggested that the same operator performs the whole assay from the beginning to the end.
Precision
Intra-Assay: CV<8% Inter-Assay: CV<10%
Detection Range
0.469-30ng/ml
Sensitivity
0.281ng/ml
Standard Curve
Results of a typical standard operation of a ANA ELISA Kit are listed below. This standard curve was generated at our lab for demonstration purpose only. Users shall obtain standard curve as per experiment by themselves. (N/A=not applicable)
Citations
Publication ()
Have you cited DEIA-BJ2332 in a publication? Let us know and earn a reward for your research.
Background
Anti-nuclear antibodies (ANA) are a diverse group of antibodies that target various nuclear and cytoplasmic antigens. These antibodies were initially found to be associated with systemic lupus erythematosus (SLE) and have now been associated with a wider range of rheumatic diseases. For example, anti-SSA/Ro and anti-SSB/La antibodies are linked to SLE and Sjögren's Syndrome (SS), while anti-dsDNA and anti-Sm antibodies are associated with SLE. Anti-histone antibodies are found in SLE and Drug-Induced Lupus, anti-RNP antibodies in mixed connective tissue disease (MCTD) and SLE, anti-Scl-70 antibodies in scleroderma (progressive systemic sclerosis), anti-Jo1 in polymyositis and dermatomyositis, and anti-centromere antibodies in CREST syndrome.
ANA testing is an essential tool in clinical immunology and rheumatology. It aids in the identification and classification of autoimmune disorders, as well as monitoring disease activity and assessing treatment response. Traditionally, ANA detection has been performed using indirect immunofluorescence (IFA) on HEp-2 cells. However, IFA has certain limitations, and ANA ELISA testing has emerged as a more robust alternative. The ANA ELISA test offers several advantages, including ease of operation and reduced reliance on the expertise required for IFA. It enables efficient screening of large numbers of patient samples and minimizes human error. The ANA ELISA test collectively detects various ANAs, including those against double-stranded DNA (dsDNA), histones, SS-A/Ro, SS-B/La, Sm, Sm/RNP, Scl-70, Jo-1, and centromeric antigens. It is important to note that a positive ANA result is not diagnostic of a specific disease but serves as an important screening tool. Further clinical evaluation, including the patient's symptoms, medical history, and additional laboratory tests, is necessary for a definitive diagnosis.
My Review for Mouse ANA (Anti-nuclear Antibody) ELISA Kit
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
New insights into the role of antinuclear antibodies in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction. Some ANAs bind DNA or associated nucleosome proteins, whereas other ANAs bind protein components of complexes of RNA and RNA-binding proteins (RBPs). Levels of anti-DNA antibodies can fluctuate widely, unlike those of anti-RBP antibodies, which tend to be stable. Because anti-DNA antibody levels can reflect disease activity, repeat testing is common; by contrast, a single anti-RBP antibody determination is thought to suffice for clinical purposes. Experience from clinical trials of novel therapies has provided a new perspective on ANA expression during disease, as many patients with SLE are ANA negative at screening despite previously testing positive. Because trial results suggest that patients who are ANA negative might not respond to certain agents, screening strategies now involve ANA and anti-DNA antibody testing to identify patients with so-called 'active, autoantibody-positive SLE'. Evidence suggests that ANA responses can decrease over time because of the natural history of disease or the effects of therapy. Together, these findings suggest that, during established disease, more regular serological testing could illuminate changes relevant to pathogenesis and disease status.
The Clinical Utility of a Positive Antinuclear Antibody Test Result
Background This retrospective study investigated the clinical utility of a positive antinuclear antibody (ANA) test performed outside of the rheumatology setting. Prior studies have investigated the frequency of ANA positivity within the general population. The purpose of this investigation was to evaluate the clinical utility of a positive ANA test result in a real-world setting by reviewing the final diagnoses of patients who were referred to a tertiary rheumatology clinic for evaluation of a positive ANA test result. Methods We reviewed the records of patients presenting to the authors between July 2007 and July 2009. Patients were included in the evaluation if they were referred for a positive ANA test result. All relevant descriptive and laboratory data were collated, as were the initial reasons for ordering ANA testing and the ultimate diagnoses reached. Positive predictive values for a "positive ANA test result" were calculated for all antinuclear antibody-associated rheumatic diseases and for lupus specifically. Results A total of 232 patients were referred for a positive ANA test result. The positive predictive value of a positive ANA test result in this cohort was 2.1% for lupus and 9.1% for any antinuclear antibody-associated rheumatic disease. No antinuclear antibody-associated rheumatic disease was identified in patients with an ANA < 1:160. The most common reason for ordering ANA testing was widespread pain (54/232, 23.2%). Conclusions In this retrospective study, more than 90% of patients who were referred to a tertiary rheumatology clinic for a positive ANA test result had no evidence for an ANA-associated rheumatic disease. The poor predictive value of a positive ANA in this cohort was largely attributable to unnecessary testing in patients with low pretest probabilities for ANA-associated rheumatic disease.
COA
Publication 
Loading ......
